Drug Trial Radar · NCT06099067
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Last checked: Nov 19, 2026Latest source record: Aug 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
239,990
Actual
Start
May 15, 2020
Primary completion
Aug 31, 2023
Study completion Aug 31, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 25, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Replication of three clinical trial emulations CANVAS, LEADER, and SAVOR TIMI that form part of the RCT-Duplicate initiative, sponsored by the FDA and delivered by the Brigham and Women's Hospital and Harvard Medical School. AstraZeneca will use the Instant Health Data platform PANALGOS (IHD) for the analyses.
Conditions
- Type 2 Diabetes Mellitus
Interventions
CanagliflozinDrug
Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication
DPP4 inhibitorDrug
DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications
LiraglutideDrug
Liraglutide dispensing claim is used as the Exposure drug in LEADER replication
SaxagliptinDrug
Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
2nd generation SulfonylureaDrug
2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-point MACETime frame: Follow up begins the day after drug initiation for the three investigated studies [a median of 134-167 days]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Gothenburg, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.